On the public citation graph
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
0 signed · 496 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.288.15.1889openalex-snapshot
Clinical Use of Bone Densitometry
inferredcites →https://doi.org/10.1001/jamaneurol.2014.3537openalex-snapshot
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
inferredcites →https://doi.org/10.1002/acn3.50972openalex-snapshot
Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
inferredcites →https://doi.org/10.1002/acn3.638openalex-snapshot
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
inferredcites →https://doi.org/10.1002/acn3.795openalex-snapshot
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
inferredcites →https://doi.org/10.1002/ana.24747openalex-snapshot
Long‐term evolution of multiple sclerosis disability in the treatment era
inferredcites →https://doi.org/10.1002/ana.24954openalex-snapshot
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
inferredcites →https://doi.org/10.1007/s10654-013-9853-4openalex-snapshot
Smoking and multiple sclerosis susceptibility
inferredcites →https://doi.org/10.1016/j.amjmed.2020.05.049openalex-snapshot
Treatment of Multiple Sclerosis: A Review
inferredcites →https://doi.org/10.1016/j.ebiom.2020.102807openalex-snapshot
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
inferredcites →https://doi.org/10.1016/s1474-4422(09)70237-6openalex-snapshot
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
inferredcites →https://doi.org/10.1016/s1474-4422(09)70258-3openalex-snapshot
Uncertain BENEFIT of early interferon beta-1b treatment
inferredcites →https://doi.org/10.1038/s41467-020-14612-6openalex-snapshot
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
inferredcites →https://doi.org/10.1038/s41582-018-0058-zopenalex-snapshot
Neurofilaments as biomarkers in neurological disorders
inferredcites →https://doi.org/10.1038/s41591-018-0304-3openalex-snapshot
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
inferredcites →https://doi.org/10.1056/nejmoa1917246openalex-snapshot
Ofatumumab versus Teriflunomide in Multiple Sclerosis
inferredcites →https://doi.org/10.1093/brain/awy154openalex-snapshot
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
inferredcites →https://doi.org/10.1093/brain/awy200openalex-snapshot
Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein?
inferredcites →https://doi.org/10.1093/braincomms/fcaa166openalex-snapshot
Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates
inferredcites →https://doi.org/10.1097/ede.0000000000000948openalex-snapshot
Validation of the Swedish Multiple Sclerosis Register
inferredcites →https://doi.org/10.1177/1352458510394701openalex-snapshot
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
inferredcites →https://doi.org/10.1177/1352458517708685openalex-snapshot
New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland
inferredcites →https://doi.org/10.1177/1352458520972573openalex-snapshot
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
inferredcites →https://doi.org/10.1177/2055217318783352openalex-snapshot
Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden
inferredcites →https://doi.org/10.1186/s12974-018-1249-7openalex-snapshot
Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
inferredcites →https://doi.org/10.1186/s12974-019-1674-2openalex-snapshot
Molecular biomarkers in multiple sclerosis
inferredcites →https://doi.org/10.1212/nxi.0000000000000555openalex-snapshot
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
inferredcites →https://doi.org/10.1212/nxi.0000000000000599openalex-snapshot
Blood neurofilament light chain at the doorstep of clinical application
inferredcites →https://doi.org/10.1212/wnl.0000000000000560openalex-snapshot
Defining the clinical course of multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.0000000000004683openalex-snapshot
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
inferredcites →https://doi.org/10.1212/wnl.0000000000007032openalex-snapshot
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
inferredcites →https://doi.org/10.1212/wnl.0000000000008319openalex-snapshot
Head-to-head drug comparisons in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.0000000000009097openalex-snapshot
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.0000000000009571openalex-snapshot
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.92.15_supplement.s12.008openalex-snapshot
Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study (S12.008)
inferredcites →https://doi.org/10.12945/j.aorta.2016.16.014openalex-snapshot
The Mystery of the Z-Score
inferredcites →https://doi.org/10.1371/journal.pone.0152347openalex-snapshot
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
inferredcites →https://doi.org/10.3390/brainsci10010056openalex-snapshot
Neurofilaments: The C-Reactive Protein of Neurology
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1001/jamaneurol.2022.5250openalex-snapshot
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.0010openalex-snapshot
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.0394openalex-snapshot
Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.3997openalex-snapshot
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.4400openalex-snapshot
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorder
inferred← citeshttps://doi.org/10.1001/jamaneurol.2025.1481openalex-snapshot
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
inferred← citeshttps://doi.org/10.1002/acn3.51622openalex-snapshot
Decreased neurofilament light chain levels in estriol‐treated multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.51676openalex-snapshot
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface
inferred← citeshttps://doi.org/10.1002/acn3.51704openalex-snapshot
Associations of sNfL with clinico‐radiological measures in a large MS population
inferred← citeshttps://doi.org/10.1002/acn3.51903openalex-snapshot
Longitudinal serum neurofilament light kinetics in post‐anoxic encephalopathy
inferred← citeshttps://doi.org/10.1002/acn3.51969openalex-snapshot
Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.51996openalex-snapshot
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.52269openalex-snapshot
Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2 ‐allelic disorders
inferred← citeshttps://doi.org/10.1002/acn3.70149openalex-snapshot
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI ‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response
inferred← citeshttps://doi.org/10.1002/acn3.70158openalex-snapshot
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis
inferred← citeshttps://doi.org/10.1002/advs.202402152openalex-snapshot
Unraveling the Pathogenesis of Post‐Stroke Depression in a Hemorrhagic Mouse Model through Frontal Lobe Circuitry and JAK‐STAT Signaling
inferred← citeshttps://doi.org/10.1002/alz.12724openalex-snapshot
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
inferred← citeshttps://doi.org/10.1002/alz.14088openalex-snapshot
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
inferred← citeshttps://doi.org/10.1002/alz.14278openalex-snapshot
Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting
inferred← citeshttps://doi.org/10.1002/alz.70343openalex-snapshot
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
inferred← citeshttps://doi.org/10.1002/ana.26446openalex-snapshot
Contributors to Serum NfL Levels in People without Neurologic Disease
inferred← citeshttps://doi.org/10.1002/ana.26913openalex-snapshot
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27054openalex-snapshot
Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27096openalex-snapshot
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27102openalex-snapshot
Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27142openalex-snapshot
Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy
inferred← citeshttps://doi.org/10.1002/ana.27144openalex-snapshot
Increased Disability Progression in rs10191329AA Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations
inferred← citeshttps://doi.org/10.1002/ana.27200openalex-snapshot
Vitamin B12 Levels Association with Functional and Structural Biomarkers of Central Nervous System Injury in Older Adults
inferred← citeshttps://doi.org/10.1002/brb3.2700openalex-snapshot
The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse‐onset multiple sclerosis
inferred← citeshttps://doi.org/10.1002/brb3.2873openalex-snapshot
Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/brb3.70165openalex-snapshot
Neurofilament Light Chain Is Associated With Acute Mountain Sickness
inferred← citeshttps://doi.org/10.1002/dad2.12321openalex-snapshot
Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
inferred← citeshttps://doi.org/10.1002/dad2.12504openalex-snapshot
Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms
inferred← citeshttps://doi.org/10.1002/dad2.12512openalex-snapshot
Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness
inferred← citeshttps://doi.org/10.1002/eji.202250228openalex-snapshot
Emerging imaging and liquid biomarkers in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/jimd.70032openalex-snapshot
Blood Biomarkers Reflecting Brain Pathology—From Common Grounds to Rare Frontiers
inferred← citeshttps://doi.org/10.1002/mds.70070openalex-snapshot
A Biomarker‐Based Classification of Corticobasal Syndrome
inferred← citeshttps://doi.org/10.1002/mus.27838openalex-snapshot
Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels
inferred← citeshttps://doi.org/10.1007/978-3-031-80849-4_5openalex-snapshot
Fluid Markers of Axonal and Neuronal Injury
inferred← citeshttps://doi.org/10.1007/s00415-022-11507-yopenalex-snapshot
Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-023-11768-1openalex-snapshot
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis
inferred← citeshttps://doi.org/10.1007/s00415-023-12021-5openalex-snapshot
Identification and management of subclinical disease activity in early multiple sclerosis: a review
inferred← citeshttps://doi.org/10.1007/s00415-023-12135-wopenalex-snapshot
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing–remitting multiple sclerosis: a 20-year follow-up cohort
inferred← citeshttps://doi.org/10.1007/s00415-024-12237-zopenalex-snapshot
Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway
inferred← citeshttps://doi.org/10.1007/s00415-024-12299-zopenalex-snapshot
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury
inferred← citeshttps://doi.org/10.1007/s00415-024-12414-0openalex-snapshot
Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjögren’s syndrome
inferred← citeshttps://doi.org/10.1007/s00415-024-12420-2openalex-snapshot
Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study
inferred← citeshttps://doi.org/10.1007/s00415-024-12434-wopenalex-snapshot
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-024-12679-5openalex-snapshot
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain–Barré syndrome
inferred← citeshttps://doi.org/10.1007/s00415-024-12701-wopenalex-snapshot
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting
inferred← citeshttps://doi.org/10.1007/s00415-024-12766-7openalex-snapshot
Biomarkers in Ataxia-Telangiectasia: a Systematic Review
inferred← citeshttps://doi.org/10.1007/s00415-025-13093-1openalex-snapshot
The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review
inferred← citeshttps://doi.org/10.1007/s00415-025-13176-zopenalex-snapshot
Annual level changes of serum neuronal and glial biomarkers in a German professional football club
inferred← citeshttps://doi.org/10.1007/s00415-025-13179-wopenalex-snapshot
Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy
inferred← citeshttps://doi.org/10.1007/s00415-025-13221-xopenalex-snapshot
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort
inferred← citeshttps://doi.org/10.1007/s00415-025-13223-9openalex-snapshot
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-025-13231-9openalex-snapshot
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)
inferred← citeshttps://doi.org/10.1007/s00415-025-13246-2openalex-snapshot
Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern
inferred← citeshttps://doi.org/10.1007/s00415-025-13249-zopenalex-snapshot
Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD
inferred← citeshttps://doi.org/10.1007/s00415-025-13271-1openalex-snapshot
Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseases
inferred← citeshttps://doi.org/10.1007/s00431-022-04793-1openalex-snapshot
Usefulness of serum neurofilament light in the assessment of neurologic outcome in the pediatric population: a systematic literature review
inferred← citeshttps://doi.org/10.1007/s00702-023-02632-7openalex-snapshot
Blood neurofilament light chain in Parkinson’s disease
inferred← citeshttps://doi.org/10.1007/s00739-025-01081-zopenalex-snapshot
Neurofilamente als potenzielle Biomarker für die bipolare affektive Störung
inferred← citeshttps://doi.org/10.1007/s00784-024-05769-1openalex-snapshot
Association between serum neurofilament light chain and periodontitis
inferred← citeshttps://doi.org/10.1007/s10072-024-07772-6openalex-snapshot
Renal function’s impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis
inferred← citeshttps://doi.org/10.1007/s10654-024-01131-7openalex-snapshot
Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults
inferred← citeshttps://doi.org/10.1007/s11306-025-02315-2openalex-snapshot
Blood metabolomics improves prediction of central nervous system damage in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s11357-023-00846-xopenalex-snapshot
Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysis
inferred← citeshttps://doi.org/10.1007/s11910-023-01300-3openalex-snapshot
Pediatric Multiple Sclerosis: Changing the Trajectory of Progression
inferred← citeshttps://doi.org/10.1007/s12975-024-01257-6openalex-snapshot
Unveiling the Hidden Impact: Hematoma Volumes Unravel Circuit Disruptions in Intracerebral Hemorrhage
inferred← citeshttps://doi.org/10.1007/s15005-023-3454-xopenalex-snapshot
Biomarker zur Abschätzung der Prognose und Diagnose der Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s15016-025-4025-9openalex-snapshot
Gekommen, um zu bleiben - die Rolle von Serum-NfL als Biomarker
inferred← citeshttps://doi.org/10.1007/s40120-023-00535-zopenalex-snapshot
Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
inferred← citeshttps://doi.org/10.1007/s40120-024-00654-1openalex-snapshot
Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s40120-024-00696-5openalex-snapshot
Serum Biomarkers in Transthyretin Amyloidosis: An Overview of Neurofilaments, Cardiac, Renal, and Gastrointestinal Involvement
inferred← citeshttps://doi.org/10.1007/s40263-024-01074-3openalex-snapshot
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s42451-024-00714-8openalex-snapshot
Neue lösliche Biomarker bei Multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s44411-025-00362-8openalex-snapshot
Complex Societal and Economic Impact of Sclerosis Multiplex in Slovakia: Decade-long Burden of Disease Moving Beyond Healthcare
inferred← citeshttps://doi.org/10.1016/b978-0-12-823848-6.00001-4openalex-snapshot
Multiple sclerosis: Clinical course, open questions, unmet clinical needs
inferred← citeshttps://doi.org/10.1016/b978-0-323-95702-1.00247-5openalex-snapshot
Clinical Overview of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/b978-2-294-78318-0.00016-1openalex-snapshot
Maladies inflammatoires primitives du système nerveux central
inferred← citeshttps://doi.org/10.1016/bs.acc.2022.09.006openalex-snapshot
Fluid biomarkers in Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/bs.acc.2024.06.010openalex-snapshot
Neurofilaments in neurologic disease
inferred← citeshttps://doi.org/10.1016/bs.acc.2025.01.006openalex-snapshot
Advances in neurofilament light chain analysis
inferred← citeshttps://doi.org/10.1016/j.actpha.2025.01.009openalex-snapshot
Rationnel et stratégie d’utilisation des traitements de fond de la sclérose en plaques
inferred← citeshttps://doi.org/10.1016/j.arr.2025.102739openalex-snapshot
Fluid-based biomarkers for neurodegenerative diseases
inferred← citeshttps://doi.org/10.1016/j.autrev.2023.103449openalex-snapshot
Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options
inferred← citeshttps://doi.org/10.1016/j.bbi.2024.11.001openalex-snapshot
Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.brainres.2024.149415openalex-snapshot
Kynurenine pathway dysregulation as a mechanistic link between cognitive impairment and brain damage: Implications for multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.cca.2022.08.017openalex-snapshot
Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort
inferred← citeshttps://doi.org/10.1016/j.cca.2024.119817openalex-snapshot
Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays
inferred← citeshttps://doi.org/10.1016/j.cca.2025.120447openalex-snapshot
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
inferred← citeshttps://doi.org/10.1016/j.cell.2023.03.008openalex-snapshot
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.116326openalex-snapshot
Gut-derived metabolites drive Th17 cell pathogenicity in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.clinbiochem.2023.110680openalex-snapshot
Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population
inferred← citeshttps://doi.org/10.1016/j.diabres.2023.110988openalex-snapshot
Serum neurofilament light chain – A potential biomarker for polyneuropathy in type 2 diabetes?
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112098openalex-snapshot
Serum Neurofilament Light Chain and Structural and Functional Nerve Fiber Loss in Painful and Painless Diabetic Polyneuropathy
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104456openalex-snapshot
A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104573openalex-snapshot
Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104662openalex-snapshot
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104781openalex-snapshot
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.104970openalex-snapshot
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105072openalex-snapshot
Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2024.117473openalex-snapshot
Metal mixtures exposure with risk of elevated serum neurofilament light chain concentrations in U.S. general adults, NHANES 2013–2014
inferred← citeshttps://doi.org/10.1016/j.ejpn.2023.05.003openalex-snapshot
Serum Neurofilament light chain (NfL) levels in children with and without neurologic diseases
inferred← citeshttps://doi.org/10.1016/j.ejrad.2023.111019openalex-snapshot
Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.ensci.2025.100550openalex-snapshot
The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.
inferred← citeshttps://doi.org/10.1016/j.ibneur.2025.05.008openalex-snapshot
A study on structural imaging changes and serum neurofilament light chain (NfL) levels in individuals with white matter hyperintensities, combining imaging techniques with biomarker analysis
inferred← citeshttps://doi.org/10.1016/j.jad.2024.01.088openalex-snapshot
Serum neurofilament light as a potential marker of illness duration in bipolar disorder
inferred← citeshttps://doi.org/10.1016/j.jad.2025.01.045openalex-snapshot
Peripheral neurofilament light chain and intracortical myelin in bipolar I disorder
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2022.577992openalex-snapshot
K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2023.578175openalex-snapshot
Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2025.578613openalex-snapshot
Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01)
inferred← citeshttps://doi.org/10.1016/j.jneuroim.2025.578739openalex-snapshot
Serum neurofilament light chain as a prognostic biomarker of glial fibrillary acidic protein autoimmunity
inferred← citeshttps://doi.org/10.1016/j.jns.2022.120380openalex-snapshot
Neurofilaments in neurologic disorders and beyond
inferred← citeshttps://doi.org/10.1016/j.jns.2023.122841openalex-snapshot
Neurologic involvement in cystinosis: Focus on brain lesions and new evidence of four-repeat (4R-) Tau immunoreactivity
inferred← citeshttps://doi.org/10.1016/j.jns.2024.123070openalex-snapshot
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing
inferred← citeshttps://doi.org/10.1016/j.jns.2024.123115openalex-snapshot
Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.jns.2025.123397openalex-snapshot
Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy
inferred← citeshttps://doi.org/10.1016/j.jns.2025.123562openalex-snapshot
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.jns.2025.123669openalex-snapshot
The expanding clinical utility of blood neurofilament light chain (bNfL): a multi-disciplinary diagnostic tool
inferred← citeshttps://doi.org/10.1016/j.lanepe.2024.101009openalex-snapshot
Fluid biomarkers in multiple sclerosis: from current to future applications
inferred← citeshttps://doi.org/10.1016/j.msard.2022.103790openalex-snapshot
Do we need more clinical trials in secondary progressive MS?
inferred← citeshttps://doi.org/10.1016/j.msard.2022.104096openalex-snapshot
CSF β-amyloid is not a prognostic marker in multiple sclerosis patients
inferred← citeshttps://doi.org/10.1016/j.msard.2022.104118openalex-snapshot
Oligoclonal M bands unveil occult inflammation in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2022.104176openalex-snapshot
sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients
inferred← citeshttps://doi.org/10.1016/j.msard.2022.104489openalex-snapshot
Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue – a secondary analysis of a randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.msard.2023.104567openalex-snapshot
Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: A pilot study
inferred← citeshttps://doi.org/10.1016/j.msard.2023.104695openalex-snapshot
Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes
inferred← citeshttps://doi.org/10.1016/j.msard.2023.104704openalex-snapshot
High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases
inferred← citeshttps://doi.org/10.1016/j.msard.2023.104893openalex-snapshot
Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients
inferred← citeshttps://doi.org/10.1016/j.msard.2023.104998openalex-snapshot
Are we there yet? The holy grail: A biomarker for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2023.105131openalex-snapshot
Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105644openalex-snapshot
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105701openalex-snapshot
Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105729openalex-snapshot
Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105734openalex-snapshot
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105747openalex-snapshot
Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105748openalex-snapshot
Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105809openalex-snapshot
The interaction between exercise and neurofilament light chain in multiple sclerosis: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105815openalex-snapshot
Comparison of SIMOA and VEUS technologies for serum neurofilament light chain measurement in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105838openalex-snapshot
Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105881openalex-snapshot
Markers of secondary progression in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105901openalex-snapshot
Neurofilaments light chains as a diagnostic and predictive biomarker for Tunisian Multiple Sclerosis patients
inferred← citeshttps://doi.org/10.1016/j.msard.2024.106166openalex-snapshot
Neurofilament light in serum: Reference values and effect of risk factors for multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106423openalex-snapshot
Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106534openalex-snapshot
Neurofilament light chain predict disease activity and disability Progression in Korean patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106550openalex-snapshot
The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106637openalex-snapshot
Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106655openalex-snapshot
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106671openalex-snapshot
Examining changes in neurofilament light chain following a behavioral weight loss intervention for adults with multiple sclerosis and obesity
inferred← citeshttps://doi.org/10.1016/j.ncl.2023.06.003openalex-snapshot
Leveraging Real-World Evidence and Observational Studies in Treating Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.ncl.2023.06.004openalex-snapshot
Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.ncl.2023.06.008openalex-snapshot
Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.nerep.2024.100211openalex-snapshot
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
inferred← citeshttps://doi.org/10.1016/j.neubiorev.2023.105035openalex-snapshot
Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction – A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.neuron.2023.05.017openalex-snapshot
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
inferred← citeshttps://doi.org/10.1016/j.neurot.2025.e00588openalex-snapshot
Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions
inferred← citeshttps://doi.org/10.1016/j.nicl.2022.103099openalex-snapshot
Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study
inferred← citeshttps://doi.org/10.1016/j.nrl.2025.501928openalex-snapshot
Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases
inferred← citeshttps://doi.org/10.1016/j.pediatrneurol.2023.07.002openalex-snapshot
Fulminant Anti-Myelin Oligodendrocyte Glycoprotein-Associated Cerebral Cortical Encephalitis: Case Series of a Severe Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Phenotype
inferred← citeshttps://doi.org/10.1016/j.pediatrneurol.2025.07.016openalex-snapshot
Rett Syndrome: Specific MECP2 Variants are Associated With Elevated Serum Neurofilament Light Chain
inferred← citeshttps://doi.org/10.1016/j.pnpbp.2024.111189openalex-snapshot
Plasma neurofilament light chain levels are associated with delirium tremens in patients with alcohol use disorder
inferred← citeshttps://doi.org/10.1016/j.schres.2024.04.003openalex-snapshot
Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis
inferred← citeshttps://doi.org/10.1016/j.scitotenv.2024.171893openalex-snapshot
Association between volatile organic compounds and serum neurofilament light chain in US adults
inferred← citeshttps://doi.org/10.1016/j.tjnut.2024.07.007openalex-snapshot
Serum Fatty Acid Profiles and Neurofilament Light Chain Levels in the General Population
inferred← citeshttps://doi.org/10.1016/j.ttbdis.2024.102383openalex-snapshot
Posterior reversible encephalopathy syndrome in early lyme neuroborreliosis
inferred← citeshttps://doi.org/10.1016/s0140-6736(25)01389-3openalex-snapshot
Alzheimer's disease outlook: controversies and future directions
inferred← citeshttps://doi.org/10.1016/s0246-0378(23)46806-6openalex-snapshot
10.1016/s0246-0378(23)46806-6
inferred← citeshttps://doi.org/10.1016/s1474-4422(22)00200-9openalex-snapshot
Diagnosis and classification of optic neuritis
inferred← citeshttps://doi.org/10.1016/s1474-4422(22)00479-3openalex-snapshot
Multiple sclerosis in 2022: old players, new insights
inferred← citeshttps://doi.org/10.1016/s1474-4422(23)00210-7openalex-snapshot
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study
inferred← citeshttps://doi.org/10.1016/s1474-4422(23)00284-3openalex-snapshot
NfL is ready for translation into paediatrics
inferred← citeshttps://doi.org/10.1016/s1474-4422(25)00249-2openalex-snapshot
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications
inferred← citeshttps://doi.org/10.1016/s1634-7072(24)49342-2openalex-snapshot
Sclerosi multipla: aspetti evolutivi e prognostici
inferred← citeshttps://doi.org/10.1017/neu.2023.25openalex-snapshot
Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders
inferred← citeshttps://doi.org/10.1038/s41380-024-02524-6openalex-snapshot
Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
inferred← citeshttps://doi.org/10.1038/s41408-024-01118-3openalex-snapshot
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms
inferred← citeshttps://doi.org/10.1038/s41467-023-42682-9openalex-snapshot
Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
inferred← citeshttps://doi.org/10.1038/s41467-025-61751-9openalex-snapshot
Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers
inferred← citeshttps://doi.org/10.1038/s41467-025-63736-0openalex-snapshot
Geometrically-engineered human motor assembloids-on-a-chip for neuromuscular interaction readout and hypoxia-driven disease modeling
inferred← citeshttps://doi.org/10.1038/s41531-023-00605-xopenalex-snapshot
Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease
inferred← citeshttps://doi.org/10.1038/s41531-025-00888-2openalex-snapshot
Early detection of Parkinson’s disease through multiplex blood and urine biomarkers prior to clinical diagnosis
inferred← citeshttps://doi.org/10.1038/s41531-025-01128-3openalex-snapshot
Predicting cognition after subthalamic Deep Brain Stimulation in Parkinson’s Disease
inferred← citeshttps://doi.org/10.1038/s41582-024-00955-xopenalex-snapshot
Neurofilaments as biomarkers in neurological disorders — towards clinical application
inferred← citeshttps://doi.org/10.1038/s41582-025-01115-5openalex-snapshot
Advancing multiple sclerosis management in older adults
inferred← citeshttps://doi.org/10.1038/s41583-024-00823-zopenalex-snapshot
The neuropathobiology of multiple sclerosis
inferred← citeshttps://doi.org/10.1038/s41591-024-02938-3openalex-snapshot
An autoantibody signature predictive for multiple sclerosis
inferred← citeshttps://doi.org/10.1038/s41598-022-20398-yopenalex-snapshot
Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
inferred← citeshttps://doi.org/10.1038/s41598-023-29704-8openalex-snapshot
Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study
inferred← citeshttps://doi.org/10.1038/s41598-024-57093-zopenalex-snapshot
Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases
inferred← citeshttps://doi.org/10.1038/s41598-024-60025-6openalex-snapshot
Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis
inferred← citeshttps://doi.org/10.1038/s41598-024-60497-6openalex-snapshot
A novel imaging marker of cortical “cellularity” in multiple sclerosis patients
inferred← citeshttps://doi.org/10.1038/s41598-024-71603-zopenalex-snapshot
Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation
inferred← citeshttps://doi.org/10.1038/s41598-024-73537-yopenalex-snapshot
Investigation of serum neurofilament light chain as a biomarker in Fabry disease
inferred← citeshttps://doi.org/10.1038/s41598-024-75290-8openalex-snapshot
The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis
inferred← citeshttps://doi.org/10.1038/s41598-025-13367-8openalex-snapshot
Pilot study of cerebrospinal fluid biomarkers reveals inflammatory changes in patients with paranoid schizophrenia
inferred← citeshttps://doi.org/10.1038/s41598-025-95773-6openalex-snapshot
Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis optica spectrum disorders versus multiple sclerosis
showing the first 200 of 458 · page through all 458
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.